You are here

VIR-5818

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Stock Titan

Wed, 01/8/25 - 11:12 am

Vir Biotechnology

metastatic castration-resistant prostate cancer